Charles River Laboratories posts investor presentation on growth strategy, demand trends and 2026 outlook

Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

CRL

0.00
  • Charles River outlined 2026 guidance reflecting completed May divestitures, projecting organic revenue down 1.5% to 0.5%.
  • Non-GAAP operating margin forecast to rise about 120-150 bps versus 19.8% in 2025.
  • EPS outlook set at GAAP USD 5.35-5.85; non-GAAP USD 10.8-11.3; free cash flow targeted at USD 375-400 million.
  • 1Q26 revenue rose 1.2% to USD 995.8 million; non-GAAP operating margin fell to 16.3% from 19.1%.
  • Cost program targets over USD 100 million incremental savings in 2026; over USD 300 million annualized savings over time.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.